Doylestown, PA – According to filings with the U.S. Securities and Exchange Commission, imCare Biotech is raising $1,777,419.00 in new funding. Sources indicate as part of senior management President and Chief Scientific Officer, Xuanyong Lu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About imCare Biotech

ImCare Biotech is a biotechnology company founded in 2011 by Dr. Xuanyong Lu, formerly a professor at Drexel University’s Institute for Biotechnology and Virology. The company’s primary products in development are innovative diagnostic biomarkers as well as developmental drugs for the treatment of liver diseases such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). ImCare Biotech’s main R&D center is located in Doylestown, PA, USA and includes a modern fully-equipped laboratory focused on molecular biology and tissue cultures. The company has an operational presence in the US. Our mission is to provide quality diagnostic and pharmaceutical products for the treatment of cancers, viral infections, and other long-term illnesses and improve the standard of care for patients and their loved ones. With research and innovation as the heart of our company, we hope to use deliver high-quality commercial products through smart and focused product development.

To learn more about imCare Biotech, visit http://www.imcarebiotech.com/

Contact:
Xuanyong Lu, President and Chief Scientific Officer
267-895-1773
https://www.linkedin.com/in/xuanyonglu/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved